Search

CRISPR Therapeutics AG

Gesloten

SectorGezondheidszorg

53.5 -0.91

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

52.01

Max

53.83

Belangrijke statistieken

By Trading Economics

Inkomsten

-91M

-214M

Verkoop

8.7M

10M

EPS

-0.94

Winstmarge

-2,102.79

Werknemers

393

EBITDA

7.3M

-110M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+37.67% upside

Dividenden

By Acuity

Volgende Winsten

9 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

572M

5.2B

Vorige openingsprijs

54.41

Vorige sluitingsprijs

53.5

Nieuwssentiment

By Acuity

32%

68%

112 / 340 Rangschikking in Healthcare

CRISPR Therapeutics AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 aug 2026, 19:16 UTC

CRISPR Therapeutics AG shares are lower today amid broader investor caution following a decline in U.S. retail sales for July.

13 aug 2026, 23:46 UTC

Correlated Moves

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting a positive trend in the biotechnology sector amid favorable economic conditions.

11 aug 2026, 19:21 UTC

CRISPR Therapeutics AG shares are trading higher amid rising oil prices and inflation concerns ahead of upcoming U.S. inflation data. No specific news was identified.

10 aug 2026, 23:06 UTC

No specific news was identified for CRISPR Therapeutics AG, which traded roughly flat during after-market hours, remaining near the upper end of its one-month range.

7 aug 2026, 20:06 UTC

News
Correlated Moves
Social Media

CRISPR Therapeutics AG is gaining amid positive social media sentiment and bullish chart patterns, aligning with the upward trend in the ARK Genomic Revolution ETF.

6 aug 2026, 22:06 UTC

Correlated Moves

CRISPR Therapeutics AG shares are higher in after-market hours, aligning with positive trends in the biotechnology sector and maintaining a position above its 20-day moving average.

5 aug 2026, 23:16 UTC

CRISPR Therapeutics AG shares traded lower in after-market hours, settling above the 20-day moving average and within the middle of its one-month range.

4 aug 2026, 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, following a volatile session with no specific news identified to explain the movement.

3 aug 2026, 23:02 UTC

Social Media
News

CRISPR Therapeutics reported second-quarter revenue of $10.18 million, exceeding expectations. Shares are trading higher in after-market hours following the earnings report.

31 jul 2026, 23:06 UTC

Shares of CRISPR Therapeutics AG are trading higher in after-market hours. The stock remains near the lower end of its one-month trading range.

30 jul 2026, 23:02 UTC

News

CRISPR Therapeutics shares are lower in after-market hours amid broader market weakness, despite analysts projecting revenue growth and a price target of $83.53.

29 jul 2026, 22:01 UTC

CRISPR Therapeutics AG shares are lower in after-market trading amid broader market declines driven by geopolitical tensions and caution ahead of the Fed's interest rate decision.

28 jul 2026, 23:01 UTC

Correlated Moves

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting broader market trends and a decline in the Russell 2000 Index.

27 jul 2026, 19:07 UTC

CRISPR Therapeutics AG shares are higher today, gaining since Friday's close. The stock peaked earlier in the session before pulling back.

23 jul 2026, 10:36 UTC

CRISPR Therapeutics AG shares are roughly flat in pre-market hours, with no specific company news identified. The stock remains near the lower end of its trading range.

22 jul 2026, 23:06 UTC

CRISPR Therapeutics AG shares are trading higher in after-market hours, though they remain below their 20-day moving average and near the lower end of their one-month range.

21 jul 2026, 19:26 UTC

News
Correlated Moves

CRISPR Therapeutics AG shares are higher today, buoyed by a strong gene-editing pipeline and positive analyst sentiment regarding its lead asset, CASGEVY.

20 jul 2026, 23:22 UTC

CRISPR Therapeutics AG is trading higher in after-market hours, despite broader market declines linked to rising treasury yields. No specific news was identified.

Peer Vergelijking

Prijswijziging

CRISPR Therapeutics AG Prognose

Koersdoel

By TipRanks

37.67% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 74.33 USD  37.67%

Hoogste 110 USD

Laagste 45 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor CRISPR Therapeutics AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

13 ratings

8

Buy

5

Hold

0

Sell

Sentiment

By Acuity

112 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat